Drugs / BR3006-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05951946 | Jul → Sep 2023 | diabetes mellitus | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR3006-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05951946 ↗ |
| Route | Oral | “take investigational products orally with 150 mL of water at room temperature” NCT05951946 ↗ |